Managing drug-refractory ventricular tachycardia presents a profound clinical challenge in modern cardiac electrophysiology. Patients who experience recurrent ventricular arrhythmias despite antiarrhythmic therapies and prior catheter interventions often face high mortality. Consequently, electrophysiologists continually seek non-thermal technologies capable of penetrating fibrotic myocardium without damaging adjacent vascular or nervous structures. The emergence of focal pulsed-field ablation represents an important advancement for this complex cohort. Recently, researchers reported the first United States experience using the novel FARAPOINT catheter for refractory ventricular tachycardia. This report offers critical insights into the procedural feasibility, acute efficacy, and short-term safety of focal irreversible electroporation in patients with severe underlying structural heart disease.

Clinical Challenges in Managing Refractory Ventricular Tachycardia

Sustained monomorphic ventricular tachycardia commonly originates from complex intramural circuits embedded in dense myocardial scar tissue. Conventional thermal ablation platforms, such as radiofrequency energy, often fail to create durable, transmural lesions across thick ventricular walls. Furthermore, scarred myocardial substrates frequently impede thermal energy transfer, leaving arrhythmogenic channels intact within deeper tissue layers. When thermal procedures fail, patients suffer recurrent arrhythmia episodes, painful implantable cardioverter-defibrillator discharges, and progressive heart failure exacerbations. In addition, antiarrhythmic medications demonstrate limited long-term efficacy and carry significant risks of organ toxicity. Therefore, cardiac electrophysiologists require an alternative energy source that effectively homogenizes deep arrhythmogenic substrates while avoiding excessive thermal injury. Novel non-thermal modalities provide a compelling therapeutic alternative for these refractory cases. Consequently, specialists are turning toward non-thermal electroporation to overcome traditional anatomical limitations. By delivering rapid electric fields, clinicians can target recalcitrant arrhythmias in patients who have exhausted standard electrophysiological treatment options.

Mechanisms of Focal Pulsed-Field Ablation in Scarred Tissue

Pulsed-field ablation operates via irreversible electroporation, applying ultrashort, high-voltage electrical fields directly to arrhythmogenic tissue. These electrical pulses form irreversible nanoscale pores in cell membranes, ultimately inducing targeted apoptosis and cell death. Unlike radiofrequency or cryoablation, focal pulsed-field ablation transfers energy non-thermally. Consequently, this technology dramatically minimizes the risk of collateral injury to adjacent critical structures, including the coronary arteries, phrenic nerve, and esophageal wall. Furthermore, cardiac myocytes exhibit lower electroporation thresholds than surrounding fibrous tissue or blood vessels. This differential sensitivity enables electrophysiologists to deliver effective lesions across heterogeneous ventricular scars with greater anatomical selectivity. In addition, focal pulsed-field ablation catheters provide flexible contact, steerable manipulation, and point-by-point energy delivery. While multielectrode basket or circular catheters excel in pulmonary vein isolation, ventricular tachycardia ablation demands precise focal maneuverability. Therefore, focal catheters permit operators to negotiate trabeculations, papillary muscles, and outflow tract anatomy safely. As a result, electrophysiologists can achieve reliable lesion delivery in anatomically demanding ventricular environments.

Study Design and Procedural Protocol in the VA Health System

The multicenter investigation evaluated ten consecutive high-risk patients who underwent ventricular tachycardia ablation between July 2025 and May 2026. The electrophysiology team conducted this pioneering registry across a single Veteran Affairs Health Care System in the United States. Notably, all enrolled individuals presented with drug-refractory sustained monomorphic ventricular tachycardia. The cohort had a median age of 77 years and included patients with ischemic and nonischemic cardiomyopathy. Furthermore, sixty percent of the patients had already undergone at least one prior failed catheter ablation procedure. These baseline characteristics illustrate the high clinical complexity of this refractory patient population. During each procedure, electrophysiologists deployed the FARAPOINT focal pulsed-field ablation catheter manufactured by Boston Scientific. The team utilized high-density electroanatomical mapping to delineate scarred myocardium and identify critical re-entrant channels before ablation. In addition, the operators delivered targeted focal pulsed-field applications to eliminate local abnormal ventricular activity. Throughout each intervention, the clinical team monitored hemodynamics continuously to ensure procedural safety.

Acute Procedural Success and Electrophysiological Outcomes

The study demonstrated exceptional acute procedural efficacy within this high-risk patient cohort. Specifically, operators achieved acute non-inducibility in all nine patients who underwent formal post-ablation programmed electrical stimulation. Non-inducibility represents the primary electrophysiological benchmark for successful ventricular tachycardia ablation. Furthermore, achieving non-inducibility strongly correlates with improved short-term clinical outcomes and reduced immediate arrhythmia recurrence. The FARAPOINT catheter allowed electrophysiologists to target critical scar channels with precise focal applications. In addition, the operators accessed challenging intracardiac sites without sacrificing catheter contact or stability. Remarkably, the registry documented zero acute procedural complications, confirming excellent initial device safety. The operators recorded no instances of pericardial tamponade, stroke, acute coronary spasm, or periprocedural death. Consequently, these findings validate the acute efficacy of focal electroporation in deep, fibrotic ventricular substrates. Electrophysiologists can therefore approach refractory ventricular arrhythmias with greater technical precision, delivering definitive therapy even in patients with previous ablation failures.

Mid-Term Clinical Observations and Future Directions

Following ablation, the investigators followed the ten patients over a median duration of 95.5 days. During this surveillance period, sustained ventricular tachycardia recurred in four out of ten patients. Nevertheless, none of the patients required repeat ablation procedures or escalation to mechanical circulatory support. Furthermore, zero mortalities occurred during the follow-up window, demonstrating acceptable mid-term stability in an elderly, multimorbid cohort. Although forty percent of patients experienced recurrent arrhythmias, clinicians must consider the severely diseased baseline substrate of this population. Most patients had already failed multiple antiarrhythmic regimens and prior thermal ablations. Therefore, achieving arrhythmia control without catastrophic hemodynamic collapse represents a meaningful clinical achievement. In addition, the absence of late complications confirms the biological safety profile of focal irreversible electroporation. However, larger prospective randomized trials remain necessary to refine dosing parameters and assess long-term rhythm outcomes. Ultimately, focal pulsed-field ablation provides an invaluable tool that may transform future ventricular arrhythmia management globally.

Frequently Asked Questions

What is focal pulsed-field ablation and how does it function?

Focal pulsed-field ablation delivers ultra-short, high-voltage electrical fields to target myocardium, inducing irreversible electroporation. This non-thermal mechanism creates permanent nanoscale pores across cell membranes, triggering cellular apoptosis. Unlike radiofrequency or cryothermal ablation, pulsed-field energy selectively targets cardiac myocytes while sparing adjacent blood vessels, nerves, and fibrous tissues. Consequently, electrophysiologists can create deep, precise lesions within scarred ventricular substrates with minimal risk of collateral thermal injury or systemic complications.

Why is the FARAPOINT catheter significant for refractory ventricular tachycardia?

The FARAPOINT catheter introduces a specialized focal platform optimized for pulsed-field energy delivery and high-density mapping. While multielectrode pulsed-field catheters excel at atrial fibrillation ablation, complex ventricular arrhythmias require fine focal manipulation. Therefore, this steerable point-by-point device allows electrophysiologists to navigate irregular trabeculated anatomy, reach deep intramural reentry circuits, and deliver tailored non-thermal lesions to arrhythmogenic substrates that previously failed conventional radiofrequency catheter ablation.

What did the initial clinical experience reveal regarding safety and efficacy?

The initial clinical registry revealed excellent acute efficacy, with operators achieving complete non-inducibility in all tested patients. Furthermore, investigators observed zero procedural complications, coronary occlusions, or periprocedural deaths during the interventions. Although four out of ten patients experienced ventricular arrhythmia recurrence during the 95-day follow-up, none required repeat ablation, mechanical circulatory support, or emergency intervention, highlighting the overall safety and clinical viability of this emerging technology.

Disclaimer: This content is for informational and educational purposes only and is not intended to substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Reyes JL et al. First United States Experience With Focal Pulsed-Field Ablation Using the FARAPOINT Catheter for Refractory Ventricular Tachycardia. J Cardiovasc Electrophysiol. 2026 Sep 13. doi: 10.1111/jce.70498. PMID: 42732570.
2. Padisak A, Szegedi N, Tanai C, et al. Pulsed field ablation for ventricular arrhythmias with pentaspline catheter. J Cardiovasc Electrophysiol. 2025;36(8):1782-1790.
3. Reddy VY, Neuzil P, Koruth JS, et al. Pulsed Field Ablation of Persistent Atrial Fibrillation With Continuous ECG Monitoring Follow-Up: ADVANTAGE AF. Circulation. 2025;151(4):254-266.